Cytokinetics eyes expanded use of heart drug after promising late-stage data | Reuters

Cytokinetics reports positive late-stage data for heart drug aficamten

Cytokinetics announced detailed late-stage trial results showing its drug aficamten significantly improved symptoms and exercise capacity in patients with non-obstructive hypertrophic cardiomyopathy, a genetic heart condition with no approved treatments.